Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Definitive Healthcare Corp. Market Cap
Based on ratings from 13 stock analysts, the Definitive Healthcare Corp. stock price is expected to increase by 11.58% in 12 months. This is calculated by using the average 12-month stock price forecast for Definitive Healthcare Corp.. The lowest target is $4 and the highest is $7. Please note analyst price targets are not guaranteed and could be missed completely.
DH is a stock in Healthcare which has been forecasted to be worth $5.27778 as an average. On the higher end, the forecast price is $7 USD by Saket Kalia from Barclays and on the lower end DH is forecasted to be $4 by Saket Kalia from Barclays.
These are the latest 20 analyst ratings of DH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ryan MacDonald Needham | Hold | Reiterates | Nov 8, 2024 | |
| David Larsen BTIG | Buy | $7 | Initiates | Sep 17, 2024 |
| George Hill Deutsche Bank | Hold | $5 | Maintains | Aug 9, 2024 |
| Vikram Kesavabhotla Baird | Neutral | $5 | Maintains | Aug 7, 2024 |
| Saket Kalia Barclays | Equal-Weight | $4 | Maintains | Aug 7, 2024 |
| Craig Hettenbach Morgan Stanley | Equal-Weight | $5 | Maintains | Aug 6, 2024 |
| Ryan MacDonald Needham | Hold | Reiterates | Aug 6, 2024 | |
| Saket Kalia Barclays | Equal-Weight | $6 | Maintains | Jul 31, 2024 |
| Anne Samuel JP Morgan | Underweight | $5 | Downgrade | Jul 31, 2024 |
| Ryan MacDonald Needham | Hold | Reiterates | Jul 31, 2024 | |
| Vikram Kesavabhotla Baird | Neutral | $6 | Maintains | Jul 31, 2024 |
| David Grossman Stifel | Buy | $7.5 | Maintains | Jul 31, 2024 |
| George Hill Deutsche Bank | Hold | $7 | Maintains | May 9, 2024 |
| Saket Kalia Barclays | Equal-Weight | $7 | Maintains | May 9, 2024 |
| Craig Hettenbach Morgan Stanley | Equal-Weight | $9 | Downgrade | May 8, 2024 |
| David Hynes Canaccord Genuity | Hold | $8 | Maintains | May 8, 2024 |
| Ryan MacDonald Needham | Hold | Reiterates | May 8, 2024 | |
| David Grossman Stifel | Buy | $9.5 | Maintains | May 8, 2024 |
| Saket Kalia Barclays | Equal-Weight | $11 | Maintains | Mar 1, 2024 |
| David Hayes Canaccord Genuity | Hold | $10 | Maintains | Feb 29, 2024 |
When did it IPO
2021
Staff Count
950
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Kevin D. Coop
Market Cap
$546.4M
In 2023, DH generated $251.4M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that DH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Definitive Healthcare (DH) shares are rising, supported by positive earnings estimate revisions, suggesting potential further gains in the near term.
Why It Matters - Solid earnings estimate revisions for Definitive Healthcare suggest improved financial performance, potentially driving share price gains and attracting investor interest.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Investors are comparing Definitive Healthcare Corp. (DH) and Privia Health (PRVA) for value opportunities in Medical Info Systems stocks.
Why It Matters - The comparison of Definitive Healthcare and Privia Health signals potential investment opportunities, highlighting which stock may provide better value amidst market fluctuations.
Sun, 10 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Definitive Healthcare Corp. (NASDAQ:DH) will hold its Q3 2024 earnings call on November 7, 2024, at 5:00 PM ET, featuring key company executives and analysts.
Why It Matters - The Q3 earnings call provides insights into Definitive Healthcare's financial performance and future outlook, crucial for assessing its growth potential and investment value.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The Company reported third quarter revenue above expectations and announced a $100 million stock repurchase authorization.
Why It Matters - Exceeding revenue guidance signals strong performance, potentially boosting stock prices. The $100 million repurchase authorization suggests confidence in the company's value, which can enhance shareholder returns.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Definitive Healthcare Corp. (DH) reported Q3 earnings of $0.10 per share, surpassing the Zacks Consensus Estimate of $0.08 and up from $0.09 per share year-over-year.
Why It Matters - Definitive Healthcare's earnings beat estimates and show year-over-year growth, signaling strong performance and potential for future growth, positively influencing investor sentiment.
Tue, 29 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investors are comparing Definitive Healthcare Corp. (DH) and GE HealthCare Technologies (GEHC) for potential value opportunities in Medical Info Systems stocks.
Why It Matters - The comparison between Definitive Healthcare and GE HealthCare highlights potential investment opportunities, guiding decisions based on current valuations and market positioning.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
